Carl Zeiss Meditec AG (XSWX:AFX) NonCurrent Deferred Revenue: CHF0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:AFX Carl Zeiss Meditec AG XSWX:AFX
70 GF Score
Price CHF27.56
GF Value CHF66.50
! 4 Warning Signs
View Full Analysis

What is Carl Zeiss Meditec AG NonCurrent Deferred Revenue?

Carl Zeiss Meditec AG XSWX:AFX 70 NonCurrent Deferred Revenue is CHF0 Mil as of Dec. 2025. GuruFocus rates XSWX:AFX with a GF Score™ of 70/100 and a GF Value™ of CHF66.50. The stock has 4 warning signs investors should review.

Non-Current Deferred Revenue represents the non-current portion of deferred revenue amount as of the balance sheet date. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months.

Carl Zeiss Meditec AG's non-current deferred revenue for the quarter that ended in Dec. 2025 was CHF0 Mil.

Carl Zeiss Meditec AG NonCurrent Deferred Revenue Related Terms

Carl Zeiss Meditec AG NonCurrent Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Carl Zeiss Meditec AG's NonCurrent Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carl Zeiss Meditec AG NonCurrent Deferred Revenue Chart

Carl Zeiss Meditec AG Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
NonCurrent Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Carl Zeiss Meditec AG Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
NonCurrent Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XSWX:AFX
70GF Score
Carl Zeiss Meditec AG XSWX:AFX
NonCurrent Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Revenue of CHF0 Mil mean?
Carl Zeiss Meditec AG (XSWX:AFX) has a NonCurrent Deferred Revenue of CHF0 Mil as of Dec. 2025. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Carl Zeiss Meditec AG and its competitors.
Is Carl Zeiss Meditec AG's NonCurrent Deferred Revenue too high?
Carl Zeiss Meditec AG's current NonCurrent Deferred Revenue is CHF0 Mil. Overall, Carl Zeiss Meditec AG has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's NonCurrent Deferred Revenue compare to ISRG and BDX?
Carl Zeiss Meditec AG's NonCurrent Deferred Revenue of CHF0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Revenue for a Medical Devices & Instruments company?
A good NonCurrent Deferred Revenue depends on the Medical Devices & Instruments industry context. However, NonCurrent Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Revenue mean?
A high NonCurrent Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Carl Zeiss Meditec AG and its competitors. Carl Zeiss Meditec AG's current NonCurrent Deferred Revenue is CHF0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Carl Zeiss Meditec AG (XSWX:AFX) has a current NonCurrent Deferred Revenue of CHF0 Mil. The stock's GF Value™ is CHF66.50, compared to a current price of CHF27.56 — trading 58.6% below its estimated fair value. The current NonCurrent Deferred Revenue is CHF0 Mil. Carl Zeiss Meditec AG's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Revenue calculated?
NonCurrent Deferred Revenue is calculated from a company's financial statements. For Carl Zeiss Meditec AG (XSWX:AFX), the current NonCurrent Deferred Revenue is CHF0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carl Zeiss Meditec AG (XSWX:AFX) Overvalued in 2026?

Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued. The current stock price of CHF27.56 is trading 58.6% below its estimated GF Value™ of CHF66.50.

Key valuation signals for XSWX:AFX:

  • NonCurrent Deferred Revenue: CHF0 Mil
  • GF Value™: CHF66.50 vs. price of CHF27.56 (58.6% below fair value)
  • GF Score™: 70/100 with 4 warning signs

No single metric tells the full story. See the XSWX:AFX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Carl Zeiss Meditec AG Business Description

Address Goschwitzer Strasse 51-52, Jena, TH, DEU, 07745
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
70GF Score

Get the complete analysis for XSWX:AFX

NonCurrent Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF27.56
Price
CHF66.50
GF Value